|Age:||1 to 21 years old|
|Keywords:||Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia, B-ALL|
|Type:||Biological study, Phase 2|
The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.
= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); >= 3 months must have elapsed if prior cranial or craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if total-body irradiation (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given
= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.